Maxwell Wealth Strategies Inc. Has $1.13 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Maxwell Wealth Strategies Inc. decreased its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,293 shares of the medical research company's stock after selling 11,415 shares during the quarter. Maxwell Wealth Strategies Inc.'s holdings in Edwards Lifesciences were worth $1,132,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Centiva Capital LP bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $295,000. Stifel Financial Corp increased its stake in shares of Edwards Lifesciences by 11.9% in the third quarter. Stifel Financial Corp now owns 232,738 shares of the medical research company's stock valued at $15,358,000 after buying an additional 24,731 shares in the last quarter. Kovitz Investment Group Partners LLC raised its stake in shares of Edwards Lifesciences by 65.2% in the third quarter. Kovitz Investment Group Partners LLC now owns 23,039 shares of the medical research company's stock worth $1,520,000 after acquiring an additional 9,093 shares during the last quarter. National Bank of Canada FI boosted its position in Edwards Lifesciences by 27.7% in the 3rd quarter. National Bank of Canada FI now owns 303,853 shares of the medical research company's stock valued at $20,051,000 after buying an additional 65,982 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc acquired a new stake in Edwards Lifesciences in the third quarter worth about $162,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company's stock, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,853 shares of company stock valued at $4,534,247. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Bank of America upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Finally, Truist Financial decreased their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $78.55.

Edwards Lifesciences Stock Performance

EW traded up $1.06 on Friday, reaching $69.32. The company had a trading volume of 4,890,092 shares, compared to its average volume of 4,907,200. The stock has a market cap of $40.75 billion, a P/E ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company's fifty day moving average is $71.32 and its 200 day moving average is $70.70.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.